Patrick Soon-Shiong
Founder @ NantCapital
Port Shepstone, South Africa
Patrick Soon-Shiong is a Series E investor at NantCapital in Port Shepstone focused on Health Care and Medical. Patrick Soon-Shiong is the Founder of NantBio. He attended the University of Witwatersrand.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Patrick Soon-Shiong invests in
Stages Patrick Soon-Shiong invests in
Countries Patrick Soon-Shiong invests in
Investment Focus
Industry
- Health Care 2 (50%)
- Medical 1 (25%)
- Therapeutics 1 (25%)
- Biotechnology 1 (25%)
- Manufacturing 1 (25%)
Stage
- Series E 1 (25%)
- Post-IPO Debt 1 (25%)
- Post-IPO Equity 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SHINE Technologies
|
SHINE Medical Technologies, Inc. manufactures and supplies medical tracers and cancer treatment elements. The company offers Molybdenum-99, a light-emitting element that is administered to patients for the purpose of diagnosing and staging cancer and heart diseases. It also provides Iodine-131 that is used to treat thyroid cancer and variousabnormal thyroid conditions, including hyperthyroidism, as well as to diagnose liver function, renal blood flow, and urinary tract obstruction.The company was founded in 2010 and is headquartered in Janesville, Wisconsin. | $240M / Series E / Feb 26, 2026 | |
ImmunityBio
|
NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. The company discovers and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks. | $50M / Post-IPO Debt / Dec 12, 2022 | |
|
ImmunityBio
|
NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. The company discovers and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks. | $107M / Post-IPO Equity / Dec 12, 2022 | |
|
ImmunityBio
|
NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. The company discovers and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks. | Post-IPO Equity |
Co-Investors
Deerfield
1 deal together
Fidelity
1 deal together
Oaktree Capital Management
1 deal together
Pelican Energy Partners
1 deal together
Sumitomo Corporation of America
1 deal together
About NantCapital
They are fast entering a new age. A worldwide shift as significant as any in history. They call it The Cognitive Age. Combining the collective promise of science, technology and communication. And then making it accessible to all people.
NantCapital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Patrick Soon-Shiong
Founder
|
|||
|
Richard Binier
CEO
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Patrick Soon-Shiong invest in?
Patrick Soon-Shiong invests primarily in Health Care, Medical and Therapeutics startups, most often at Series E and Post-IPO Debt stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Patrick Soon-Shiong last invest?
The most recent investment recorded for Patrick Soon-Shiong closed in Feb 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
